Previous 10 | Next 10 |
Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTP Strong Commercial Execution Maximizing Value of Existing Portfolio: ENTYVIO ® Pen Launched...
2024-01-29 17:25:44 ET More on Halozyme Therapeutics, Takeda Pharmaceutical, etc. Halozyme Therapeutics: A Reasonable Value In An Overvalued Market Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings...
New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin (IG) Portfolio to Meet the Needs of People Living with CIDP Approval Supported by Phase 3 ADVANCE-CIDP Open-label Study Data Demonstrating Safety and Efficacy as an Intravenous Ther...
2024-01-29 06:06:17 ET The European Commission has approved Takeda's ( NYSE: TAK ) Hyqvia as maintenance therapy in patients of all ages with a neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP).... Read the full article on Seeking Alpha ...
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients an up to Once-Monthly Treatment Option At-Home or In-Office Administration Provides CIDP Patients with a Personalized Treatmen...
2024-01-26 12:47:12 ET Summary Today, we take another look at Halozyme Therapeutics, Inc., which enhances drug delivery through its ENHANZE platform, earning royalties and milestone payouts from major drugmakers. Management has plans in place to more than double royalty revenues b...
2024-01-25 17:09:29 ET More on Cognizant Technology Cognizant: 2024 Is Unlikely To Be A Repeat Of 2023 Cognizant Can Go Up And Down, But I Say 'Hold' Cognizant: I Stay Cautious For Now Read the full article on Seeking Alpha For further details see: ...
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation PR Newswire Cognizant will support Takeda's ambition to modernize technology capabilities TEANECK, N.J. , Jan. 25, 2024 /PRNewswire/ -- C...
2024-01-23 14:30:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Google “How important is sleep?” and you get three billion results . So, it stands to reason that the booming sleep industry isn’t a fad. If that’s the case, inv...
2024-01-21 13:30:00 ET Pharmaceutical companies would be wise to pay attention to developing new treatments for ADHD as there is a demand for improved drugs in the space. Currently, the medications of choice for the condition are stimulant drugs, such as Takeda's ( NYSE: TAK ) V...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...